About Professor Ian Alexander

Over the last 20 years Prof Alexander has played a central role in the establishment of the gene transfer/gene therapy field in Australia, and focused his research efforts on virus-mediated gene transfer and translational medicine.

Professor Alexander is one of Australia’s leading authorities on the development and use of recombinant viruses and has become a global leader in the development of liver-targeted gene therapy for metabolic/genetic liver disease (particularly urea cycle defects, UCDs).

Professor Alexander is a physician/scientist with research, clinical and teaching/administrative responsibilities. He received his PhD in Molecular and Cellular Biology in 1991 after completing his paediatric sub-specialty training in genetic and metabolic disease. He then undertook full-time post-doctoral research studies in Seattle, focusing on recombinant virus-mediated gene transfer, before returning to Australia in 1995 to take up his current appointments.

In 2001 his research group became the first in Australian medical history to treat a genetic disease (SCID-X1) by gene therapy (Medical Journal of Australia 182(9):458-463, 2005), and is currently involved in two further clinical trials (one national and the other international).

He is frequently consulted for his expertise by national authorities/agencies including The Department of Defence, The National Measurement Institute, and the Gene Technology Ministerial Council. In 2009 he was elected a life member of AGCTS in recognition of "Excellence and Service to the Science of Gene Therapy" and in 2015 was appointed a Fellow Australian Academy of Health and Medical Sciences reflecting peer recognition of his distinctive competencies, leadership and excellence in biomedical research.

<html />

Selected publications

For a comprehensive list of Professor Alexander's publications please see his Sydney Medical School profile page.